lixisenatide/insulin glargine (LixiLan)
Classes: Antidiabetics, Glucagon-like Peptide-1 Agonists; Antidiabetics, Long-Acting Insulins
Dosing and uses of LixiLan (lixisenatide/insulin glargine)
Type 2 Diabetes Mellitus
Pending FDA approvaL
Fixed ratio combination of insulin glargine 100 units/mL and lixisenatide, a once-daily prandial GLP-1 receptor agonist for type 2 Dm
Pediatric dosage forms and strengths
Safety and efficacy not established
Pharmacology of LixiLan (lixisenatide/insulin glargine)
Mechanism of action
Lixisenatide: Incretin mimetic; analogue of human glucagonlike peptide-1 (GLP-1); acts as GLP-1 receptor agonist to augment glucose-dependent insulin secretion
Insulin glargine: Insulin and its analogues lower blood glucose by stimulating peripheral glucose uptake, especially by skeletal muscle and fat, and by inhibiting hepatic glucose production; insulin inhibits lipolysis and proteolysis and enhances protein synthesis; targets include skeletal muscle, liver, and adipose tissue
